Миелосупресия Лечението с Tasigna се свързва с (National Cancer Institute Common Toxicity Criteria степен 3- 4) тромбоцитопения, неутропения и анемия.
Myelosuppressio Tasigna- hoito voi aiheuttaa (National Cancer Institute - laitoksen Common Toxicity Criteria- kriteerien [CTC] vaikeusasteen 3- 4) trombosytopeniaa, neutropeniaa ja anemiaa.